Navigation Links
Pest Control research Leads to Pain Control Discovery

Researchers have claimed that studies that were being conducted towards pest control have lead to the discovery of pain control. //

Researchers from the University of California, have stated that the newly discovered enzyme inhibitor, which earlier had been identified by researchers who were initially looking for biological pest controls, might actually lead to pain relief for people suffering from arthritis and other inflammatory diseases. It has been reported that a noted inflammatory disease expert has acknowledged the discovery as the most important discovery in inflammation in more than a decade, and was of the opinion that it might also reduce side effects associated with the painkiller, Vioxx.

Lead author Kara Schmelzer, a post-doctoral researcher in principal investigator Bruce Hammock's lab, tested the novel compounds on rodents and found them to be as potent at a low-dose as Vioxx and Celebrex, but without the changes in blood chemistry linked to heart attacks. Vioxx and Celebrex belong to a class of drugs known as Cox-2 inhibitors. The enzyme targeted by the newly discovered inhibitors is also found in humans. (Enzymes are proteins that speed up chemical reactions.)

'The reason this is so exciting is that this is a novel way to reduce inflammation, with a combination therapy,' Schmelzer said. 'We're going after a new enzyme target, not going after the Cox-2 inhibitors.'

Their research is reported in a paper entitled 'Enhancement of Antinociception by Co administration of Nonsteroidal Anti-Inflammatory Drugs and Soluble Epoxide Hydrolase Inhibitors,' published in the current edition of Proceedings of the National Academy of Sciences.

'Our laboratory was initially interested in regulating the development of insect larvae,' said Hammock, a distinguished professor of entomology and member of the National Academy of Sciences.” The discovery switched the focus of the research from ‘pest control to pain
'"/>




Page: 1 2 3

Related medicine news :

1. FDA Approves Birth Control Skin Patch
2. Control of inflammation
3. New Birth Control Pills increase the stroke risk
4. Control of anger disorder connected to Brain Dysfunction
5. WHO Declares Vietnam First Country to Control SARS
6. The Importance Of “ Good ”Control Of Diabetes During Pregnanc
7. Controlling Asthma during Pregnancy
8. Effective Control Of Blood Sugar Levels
9. Controlling Allergies Before They Start
10. Diabetics Can Now Be Able To Control Both Blood Sugar And Their Weight
11. Better Control Of Sugar Levels
Post Your Comments:
(Date:12/2/2008)... CHICAGO, Dec. 2 Breast-Specific ...ly sensitive imaging technique for the diagnosis o...o diagnose breast cancer. BSGI,is a molecular bre...dent of,tissue density and discover very early st...ound and magnetic resonance imaging (MRI), BSGI ha...
(Date:12/2/2008)... PHILADELPHIA, Dec. 2 U...lvania children the opportunity to become "health,... designing programs to,address it and implementin...edHealth HEROES is a service-learning, health lite...e, working through educators and youth,leaders, t...
(Date:12/2/2008)... Money may be better spent in other areas, expert...s) -- Hospital rapid response teams, created to pr...patients, do not seem to work, a new study finds. ...over the past decade," said lead researcher Dr. Pa...t Institute in Kansas City, Mo. "Earlier studies h...
(Date:12/2/2008)... , The Health Story Proje...he project formerly known as “Clinical Docum...(CDA4CDT). CDA4CDT will continue as the label for ...nd submitted to Health Level Seven (HL7) for ballo... (Business Wire EON) December 2, 2008 -- "Ou...
Breaking Medicine News(10 mins):Health News:Molecular Breast Imaging Has Greater Sensitivity Over Mammography, Ultrasound and MRI for Invasive Lobular Carcinoma 2Health News:UnitedHealth Group Grants to Help Students and Educators Combat Childhood Obesity 2Health News:Rapid Response Teams Don't Cut Hospital Heart Attacks, Death Rates 2Health News:Rapid Response Teams Don't Cut Hospital Heart Attacks, Death Rates 3Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 2Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 3Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 4Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 5
...led that there has been an increase in heart failu...s are higher among women, // with men surviving f...n the incidence of heart failures during the 1990 ...eriod, in the case of people aged over 65 years, a...
...ent has approved the drug TEMODAL in combination w...astoma multiforme brain cancer. // The drug TEMODA...ng-Plough Corporation and is used in treating two ...forme and anaplastic astrocytoma. Clinical study ...
...to India’s National Institute of Immunology are re...ch helps us to understand how the tuberculosis (TB...ll help in developing newer and more effective med...y as 2 million lives across the world annually. Th...
... the worst possible results does not serve any pur...he disappointment in the end is the same for both ...ttle Pacific University and Jonathon Brown of the ...hnique of ‘defensive pessimism’ and reported their...
Other Medicine News:
(Date:12/2/2008)...c. 2 Horizon Therapeutics, Inc., a...announced that two pivotal,Phase 3 trials evaluat...T-501,met all primary endpoints. HZT-501, a nove...taining ibuprofen and famotidine, demonstrated a,...ce of non-steroidal,anti-inflammatory drug (NSAID...
(Date:12/1/2008)... CHICAGO, Dec. 2 A stu...EM), a new technique for imaging the breast, is no...ormonal status, two factors that limit the effecti...g cancer. Results will be presented today at the a... America (RSNA). , , "The ability of PEM t...
(Date:12/1/2008)...1 S*BIO Pte Ltd today announced th...18, a potent and orally-active JAK2 inhibitor, in ...with chronic idiopathic myelofibrosis (CIMF). , ...ty and tolerability of SB1518 in patients with CIM... Phase 1 part of the study will assess the safety ...
(Date:12/1/2008)...hows the Prox1 gene is a two-way switch that, if t...e reprogrammed so that they lose their identity an..., MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNewswire/...spital have discovered that a certain differentiat...at it requires the constant expression of a gene c...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3JAMA Commentary Opposes Criminal Punishment for HIV Exposure Transmission 6916 1JAMA Commentary Opposes Criminal Punishment for HIV Exposure Transmission 6916 2JAMA Commentary Opposes Criminal Punishment for HIV Exposure Transmission 6916 3Kowa Company Ltd Acquires ProEthic Pharmaceuticals Inc 6913 1Kowa Company Ltd Acquires ProEthic Pharmaceuticals Inc 6913 2Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 6909 1Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 6909 2Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 6909 3Huifeng Bio Pharmaceutical 28HFGB 29 to Release Second Quarter 2008 Earnings Results on August 15 2008 6904 1
...ion during the,early post-operative period compare...ion in nausea in the female,patient population com... CeNeS Pharmaceuticals plc (AIM:,CEN), the Cambrid...tional data from post-hoc analysis of the recent P...nide) in over 500 patients,with post-operative pai...
...0%; mso-hyphenate: none">,BUDAPEST, Hungary, June,...sands of patients with cancer from suffering,unnec...ngress of,the European Association for Palliative ...ated whether this first in class novel,formulation...,duration of effect, mirroring the breakthrough pa...
Other Medicine Technology:Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 2Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 3Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 4Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 5Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 6Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 7Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 2Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 3Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 4Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 5Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 6
Inquire
Inquire
...nce, the SZX7 is designed for ease of use and work...ns to advanced research. The SZX7 offers one of th...ding image clarity, true color and accurate reprod...ined detail. System modularity and abundant access...
A compact stereomicroscope that is immediately ready for operation and extremely easy to use. Focused on the essential performance features, the Stemi DV4 design concept provides optimum utility.
Medicine Products: